论文部分内容阅读
一、前言麦迪霉素(SF—837,midecamycin,mydecamycin,medemyein)又译麦迪加霉素或米地加霉素,是日本明治制果会社首先发现,并于1971年报导的一个新的16元环大环内酯类抗生素。属于大环内酯类的柱晶白霉素——碳霉素族。麦迪霉素是国外1973年上市的新品种,对革兰氏阳性菌的抗菌活性强。近年来为了提高疗效,对麦迪霉素进行了化学结构的改造,合成了一系列的新衍生物,对有希望的衍生物作了药理临床试验。本文叙述麦迪霉素的菌种来源,理化性质,抗菌活性,药理试验及临床评价:对麦迪霉
I. INTRODUCTION SF-837 (midecamycin, mydecamycin, medemyein) is also translated as Madidamycin or Mitidomycin. It is the first 16 yuan reported by Meiji Shochu Club in Japan and reported in 1971 Central macrolide antibiotics. Macrolides belong to the macrolide family of carbomycins. Midecamycin is a new product introduced in foreign countries in 1973, which has strong antibacterial activity against Gram-positive bacteria. In recent years, in order to improve the curative effect, the chemical structure of midecamycin has been modified, a series of new derivatives have been synthesized and pharmacological clinical trials have been conducted on the promising derivatives. This article describes the origin of the mold of midecamycin, physical and chemical properties, antibacterial activity, pharmacological tests and clinical evaluation: